<DOC>
	<DOCNO>NCT01540435</DOCNO>
	<brief_summary>This randomize , control , multicenter , non-comparative phase II trial compare intensify perioperative treatment patient resectable synchronous metachronous colorectal liver metastases primary surgery adjuvant systemic chemotherapy .</brief_summary>
	<brief_title>Perioperative Treatment Resectable Liver Metastases</brief_title>
	<detailed_description>Recurrence rate R0-resection colorectal liver metastasis still high ( 60-70 % ) . Therefore , multidisciplinary treatment patient frequently use order achieve beneficial impact regard progression-free overall survival . The point time treatment , pre- and/or postoperative , still matter debate . In EORTC 40983 trial , perioperative chemotherapy 5-Fluorouracil oxaliplatin ( FOLFOX-Regimen ) display non-significant benefit 3 year disease free survival intent treat population ( HR 0.79 , 95 % CI 0.62 1.02 ) ( Nordlinger , Sorbye et al . 2008 ) . The combined analysis two adjuvant trial , ( non-contemporary ) 5-FU Bolus regimen , show non-significant prolongation median disease free survival ( DFS ) 18.8 27.9 month ( p=0.058 ) OS 47.3 62.2 month ( p=0.095 ) ( Mitry , Fields et al . 2008 ) . However , postoperative treatment 6 month FOLFOX often use daily practise . Thus , investigation urgently warrant . This phase II trial evaluate two strategy intensify perioperative postoperative treatment regimen . Current study establish role FOLFOXIRI regimen metastatic setting ( Falcone , Ricci et al . 2007 ) . A intensification three drug regimen bevacizumab seem feasible yielding response rate 84 % disease control rate 100 % ( Falcone 2008 ; Bruera , Santomaggio et al . 2010 ; Masi , Loupakis et al . 2010 ) . Regarding efficacy , evaluation FOLFOXIRI bevacizumab preoperative treatment resectable CLM seem promise . Postoperative treatment FOLFOX 6 month choose arm A .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Main selection criterion : 1 . Histological proven CRC completely resectable metachronous synchronous liver metastasis ( judge treat surgeon ) . 2 . Patients must undergo complete resection ( R0 ) primary tumor least 4 week randomization . Or case synchronous disease intact primary ; primary tumor R0 resectable together liver metastasis patient nonobstructive primary tumor able receive preoperative chemotherapy surgery . Synchronous rectal primary allow . 3 . Measurable hepatic disease Response Evaluation Criteria Solid Tumors ( RECIST version 1.1 ) . 4 . No evidence extrahepatic metastasis CRC . 5 . Patients must 18 75 year . 6 . ECOG Performance status ≤ 1 7 . No previous chemotherapy metastatic disease . Radiotherapy alone allow give pre post protocol treatment . 8 . Previous adjuvant chemotherapy primary CRC allow complete least 6 month inclusion study . 9 . All following test do within 4 week prior randomization Absolute neutrophil count &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L , hemoglobin &gt; 9 g/dL 5.59 mmol/l . Serum creatinine less 1.5 time upper limit normal ( ULN ) ( exclude severe renal impairment ) ; significant proteinuria ( urine dipstick proteinuria ³ 2+ . If urine dipstick ³ 2+ , 24hour urine must demonstrate £ 1 g protein 24 hour patient eligible ) . Absence major hepatic insufficiency ( bilirubin &lt; 1.5 x ULN aspartate aminotransferase ( ASAT ) /alanine aminotransferase ( ALAT ) &lt; 5 x ULN ) . Patients receive therapeutic anticoagulation must INR &lt; 1.5 ULN aPTT &lt; 1.5 ULN within 7 day prior registration . The use full dose anticoagulant allow long INR aPTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least two week time registration . 10 . No pregnancy breast feeding . Negative serum pregnancy test within 7 day start study treatment premenopausal woman woman &lt; 1 year onset menopause require enter trial . Note : negative test reconfirm urine test , 7day window exceed . 11 . Adequate contraception require 3 month study treatment male female patient risk conception exists . 12 . No major surgical procedure , open biopsy , significant traumatic injury within 4 week prior randomization . 13 . No previous exposure VEGF/VEGFRtargeting therapy within last 12 month . 14 . No thrombosis severe bleed within 6 month prior entry study ( except bleed tumor surgical resection ) evidence bleed diathesis coagulopathy . 15 . Absence peripheral neuropathy NCI CTCAEgrade ≥ 1 , active inflammatory bowel disease bowel disease cause chronic diarrhea ( define &gt; 4 loose stool per day ) , serious wound complication , ulcer , bone fracture . 16 . No evidence disease , metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatmentrelated complication . 17 . No concomitant treatment ASS &gt; 325 mg NSAIDs , know inhibit platelet function , sorivudin analog compound preparation St. John 's wort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>Perioperative treatment</keyword>
	<keyword>Liver resection</keyword>
</DOC>